The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.
For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
Firm Advises Morgan Stanley as Financial Advisor to the Special Committee of Bumble's Board of Directors in Acquisition by Ithaca Holdings
On October 13, 2026, Bumble announced that it entered into a definitive agreement to be acquired by Ithaca Holdings in an all-cash transaction valuing the company at $1.3 billion. Under the terms of the agreement, Bumble common shareholders will receive cash consideration of $6.05 per share of Class A common stock, representing an approximately 138 percent premium to the unaffected closing share price on October 9, 2026, and a premium of approximately 119 percent to the 30-day volume weighted average price as of October 9, 2026. Wilson Sonsini Goodrich & Rosati advised Morgan Stanley, who acted as financial advisor to the Special Committee of Bumble's Board of Directors.
Client Highlights
Wilson Sonsini Advises Causa Prima on $20 Million Seed Round
On October 13, 2026, Causa Prima, a company developing an autonomous finance platform for businesses, announced it has raised $20 million in a seed funding round led by Base10 Partners, bringing its total funding to $30 million. QED Investors, FJ Labs, Creandum, Kfund, and Borusan Ventures also participated in the round. Causa Prima's platform uses autonomous agents to handle communications and negotiations between businesses, including disputed invoices and early-payment requests. Wilson Sonsini Goodrich & Rosati advised Causa Prima on the transaction.
Client Highlights
Wilson Sonsini Advises Microchip Technology on Acquisition of VORAGO Technologies
On October 9, 2026, Microchip Technology, a broadline supplier of semiconductors, announced that it has acquired VORAGO Technologies, a privately held provider of radiation-hardened and radiation-tolerant microcontrollers (MCUs) and microprocessors (MPUs) based in Austin, Texas. Terms of the transaction were not disclosed. Wilson Sonsini Goodrich & Rosati advised Microchip on the transaction.
Client Highlights
Firm Advises Oxford Science Enterprises on IP Matters Related to Sensible’s $47 Million Financing
On October 6, 2026, Sensible Biotechnologies (Sensible), a biotechnology company developing a first-of-its-kind platform for naturally modified mRNA medicines, announced that it has secured $47 million in financing to advance and scale its integrated mRNA technology. The financing includes a Series A led by Oxford Science Enterprises (OSE) and up to $20 million in non-dilutive funding from the Government of Slovakia and the European Union. Wilson Sonsini Goodrich & Rosati advised OSE on IP due diligence related to the transaction.
Client Highlights
Wilson Sonsini Advises Armada Acquisition Corp. II on Business Combination with Evernorth Holdings
On October 9, 2026, Armada Acquisition Corp. II (Armada II), a special purpose acquisition company, and Evernorth Holdings (Evernorth), a digital asset treasury company building institutional access to the XRP economy, announced the completion of their business combination. Evernorth’s common stock is expected to begin trading on the Nasdaq Stock Market on October 12, 2026, under the ticker symbol “XRPN.” Investors included Arrington Capital, SBI Group, Ripple, Pantera Capital, Kraken, and GSR, among others.
Client Highlights
Wilson Sonsini Advises Solcoa Industries on $75 Million Financing
On September 24, 2026, Solcoa Industries, a rare earth metals producer, announced $75 million in financing to build Solcoa One, its first commercial rare earth metalmaking plant. The round includes $45 million in equity led by Bain Capital Ventures, with participation from Gigascale Capital, Long Journey, Felicis, Dylan Field, and prominent leaders across defense and technology. It also includes $30 million in debt and equipment financing, anchored by J.P. Morgan. Wilson Sonsini Goodrich & Rosati advised Solcoa on the transaction.
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.